Victory Capital Management Inc. Sells 1,172 Shares of Catalent, Inc. (NYSE:CTLT)

Victory Capital Management Inc. lowered its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 4.1% in the 3rd quarter, HoldingsChannel reports. The firm owned 27,360 shares of the company’s stock after selling 1,172 shares during the period. Victory Capital Management Inc.’s holdings in Catalent were worth $1,657,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of CTLT. Sumitomo Mitsui Trust Group Inc. raised its holdings in Catalent by 3.7% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company’s stock worth $24,550,000 after buying an additional 14,373 shares during the last quarter. OVERSEA CHINESE BANKING Corp Ltd lifted its position in shares of Catalent by 18.8% during the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 6,242 shares of the company’s stock worth $378,000 after acquiring an additional 988 shares in the last quarter. Wolverine Asset Management LLC lifted its holdings in shares of Catalent by 9.1% in the third quarter. Wolverine Asset Management LLC now owns 46,685 shares of the company’s stock worth $2,828,000 after buying an additional 3,908 shares in the last quarter. Crossmark Global Holdings Inc. boosted its holdings in Catalent by 2.6% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company’s stock valued at $553,000 after purchasing an additional 229 shares during the period. Finally, Olympiad Research LP grew its position in Catalent by 93.2% during the third quarter. Olympiad Research LP now owns 33,009 shares of the company’s stock worth $1,999,000 after buying an additional 15,924 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CTLT. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, StockNews.com lowered Catalent from a “hold” rating to a “sell” rating in a research report on Friday. One analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $63.40.

Catalent Stock Up 0.4 %

Shares of Catalent stock opened at $61.24 on Tuesday. The company’s 50 day moving average is $59.81 and its 200 day moving average is $58.32. The company has a market cap of $11.12 billion, a price-to-earnings ratio of -26.99, a price-to-earnings-growth ratio of 2.42 and a beta of 1.16. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. Catalent, Inc. has a twelve month low of $36.74 and a twelve month high of $61.50.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the previous year, the business posted ($0.10) earnings per share. The firm’s revenue was up 4.2% on a year-over-year basis. Research analysts anticipate that Catalent, Inc. will post 0.84 EPS for the current year.

Insider Buying and Selling at Catalent

In related news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares of the company’s stock, valued at $646,849.50. This represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,114 shares of company stock valued at $305,931 over the last 90 days. 0.31% of the stock is currently owned by corporate insiders.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.